Multivessel TALENT Trial of SMT’s Supraflex Cruz Stent Completes Enrollment

October 3, 2024—Sahajanand Medical Technologies Pvt Ltd (SMT) announced the completion of patient enrollment in the Multivessel TALENT trial, which aims to further validate the capabilities of the company’s Supraflex Cruz stents in addressing some of the most challenging coronary conditions.

The study is comparing the Supraflex Cruz with the Synergy stent (Boston Scientific Corporation) in patients with complex three-vessel coronary artery disease.

The Multivessel TALENT trial is conducted by the Corrib Research Center at the National University of Ireland in Galway, Ireland. Professor Patrick W. Serruys, MD, is Chair and Chief investigator of the trial, which enrolled 1,550 patients across Europe.

According to SMT, the Multivessel TALENT trial incorporates state-of-the-art percutaneous coronary intervention (PCI) best practices, including 100% use of quantitative flow ratio (QFR) for physiological lesion assessment; intravascular ultrasound or optical CT-guided lesion optimization to ensure the best possible outcome; 1-month dual antiplatelet therapy followed by single antiplatelet therapy using prasugrel.

Prof. Serruys commented in SMT’s press release, “We designed this important study to compare the Supraflex Cruz family of stents to the Synergy stent applying ‘best practice’ treatment principles for PCI including the Syntax II score recommendation, QFR guidance for physiology, imaging guidance for optimal stent deployment, contemporary chronic total occlusion techniques, and optimal medical therapy in patients with three-vessel coronary disease. We are very pleased that enrollment is now complete and look forward to reporting the primary endpoint results in late 2025.”

The company stated that both the Supraflex Cruz and the Synergy stents were selected for this trial based on their best-in-class performance, as evidenced by recent clinical trials. Supraflex Cruz, in particular, has demonstrated superior outcomes in complex lesions, including bifurcations, and high bleeding risk patients, supported by data from the FIRE trial and COMPARE 60/80, noted SMT in the press release.